"

Ⓜ️体育买球网址Ⓜ️全球品牌Ⓜ️体育买球网址Ⓜ️千万款游戏集于一体Ⓜ️体育买球网址Ⓜ️原生态App,迎战世界杯7x24服务,期待您的到来!

"

Next

Image
Concept map of the industrial base, the first phase has been put into production in 2019, and there are still more than 90 acres of land reserves.

Group profile

Founded by Yale University scholars and their team returning to China, HebaBiz Biotech is committed to creating personalized, precise and improved solutions for the treatment of cancers and liver diseases, guided by clinical value and patients' needs, and systematically improving the quality of traditional Chinese medicines by the use of cutting-edge biotechnology. Both of our Beijing and Guangxi entities are "National High-tech Enterprises", and our Beijing entity is a "Zhongguancun Hi-Tech Technology Enterprise" and our Guangxi entity is a "Specialized, Excellent, Featured and Innovative Enterprise". HebaBiz Biotech has established a National & Local Joint Engineering Research Center for Anti-tumor Drug Development, systematic technology platforms for small-molecule drugs and innovative traditional Chinese medicines. HebaBiz Biotech has numerous international and domestic patented technologies, and seven new drug candidates in its pipeline under research and development, including China's Category 1.1 Anti-tumor Innovative Drug...

Image

Numerous international and domestic patents

7 pipeline new drugs

And dozens of product approvals

Image

Established a National Anti-tumor Research Center

3 Provincial Research Centers

1 Postdoctoral Research Workstation

Image

68000+ square meters

Quality GMP production workshop

INNOVATIVE PIPELINE

Focusing on the clinical needs for anti-cancer and liver diseases, we have diversified product forms, mainly small-molecule chemical drugs and multi-molecule multi-target innovative Chinese medicines, which have synergistic effects with each other

Image

Notes:

(1)An international multi-center, open-label Phase II/III clinical study is being carried out, and it is planned to be implemented in Taiwan, the United States and mainland China. Other solid tumor indications such as drug-resistant renal cancer, sarcoma cancer, bladder cancer, and liver cancer will be developed in the future.

(2) In animal model tests of pancreatic cancer and liver cancer, clevudine has shown obvious anti-tumor effects, and has synergistic effects with a variety of anti-tumor drugs already on the market and the company's new drugs troxacitabine and JP001. Patients with liver cancer caused by hepatitis B have better results. Preliminary studies have found multiple targets and biomarkers.

(3) Phase I-III trial approvals have been obtained; Phase I solid tumor research has been completed, and mechanism-related research has been supplemented, and new biomarkers/targets have been discovered; renal cancer single drug (including non-clear cell carcinoma) and pancreatic cancer combination are being developed. with Phase II-III studies.

(4) The IND application stage.

Siroquine
Siroquine (JP001) is an innovative drug with drug repurpose as development strategy, which can inhibit tumor cell proliferation by regulating the autophagy pathway of tumor cells. In the phase II/III clinical trials, the obvious therapeutic effect on glioblastoma was shown, and a biomarker highly consistent with its therapeutic effect was discovered, providing further evidence for the precise and efficient development for subsequent clinical trials. FDA clinical approval has been obtained.
Image
Clevudine
Clevudine (L-FMAU) is positioned as a novel third-generation pyrimidine nucleoside analogue that has dual targeting effects on hepatitis B virus and tumor cells, and can inhibit all processes of retro-replicating HBV RNA to form viral genomes. It can be used for chronic hepatitis B, liver cancer, pancreatic cancer and other indications. It has been approved by CDE for phase III clinical study on chronic hepatitis B.
Image
Troxacitabine
Troxatabine (BCH-4556) is a nucleoside analogue with an unnatural L-configuration parent nucleus, which has significant advantages in resistance compared with traditional anticancer drugs. A number of clinical studies have been carried out abroad in the past, with a total of 855 cases for clinical safety and mainly used for the treatment of hematoma and some solid tumors such as kidney cancer, liver cancer and pancreatic cancer. HebaBiz and the original researchers have continuously deeply studied the drug mechanism of Troxacitabine and discovered its TMEDC characteristics, expected to be successful in the treatment of solid tumors. As a class 1.1 anticancer drug, it has been approved by CDE to carry out phase I-III clinical trials.
Image
Fativier
Fativier (Z018B) is derived from a molecule group extracted from a single traditional Chinese herb (homology of medicine and food), and is the key product of our multi-molecule multi-target innovative Traditional Chinese medicine track. It seeks to achieve the therapeutic purpose by simultaneously regulating glucose and lipid metabolism disorder, inflammation and liver fibrosis through multiple pathways.
Image
Yigan Mingmu Oral Liquid
Yigan Mingmu Oral Liquid is derived from a Chinese herbal formula composed of 12 crude herbs and is our exclusive OTC product approved for phase III clinical trial for alcoholic liver disease (no currently approved targeted therapy drugs), developed in accordance with modern medicine, efficacy, pharmacodynamics and pharmacology research methods. We have carried out systematic research and secondary development, exploration and practice of multiple-molecule multiple-target theory of traditional Chinese medicine, in view of modern pharmacology The supplementary nature of traditional Chinese medicine is hereby promoted to the modern Chinese medicine of precision treatment.
Image
G*obesity
G*obesity (ZL004) is a category 1 innovative medicine developed with the use of modern biotechnology and via a thorough research on the classic Chinese medicine formula composed of 4 crude herbs, for weight control, regulation of blood lipids (no currently approved drugs for safe and effective reverse metabolic dyslipidemia and obesity), and to complete our Chinese medicine development strategy for single herb, four-herbs and 12-herbs formulas, to improve systematic innovation in the area of TCM.
Image

Team

Image
James Zhou, PhD
Image
Prof. Yung-Chi Cheng
Image
Xie Baibo, PhD
Image
Cheng Linyou, PhD
Image
Li Yanru, PhD
Image
Prof. Yao Xinsheng
Image
Prof. Deng Zixin
Image
Prof. Chi Kwan Hwa, MD
Image
Prof. Pei Duanqing
Image
Prof. Zhou Aiping, MD

Important Events

Set sail
Set sail
-Establishment of the Company
-Dr. James Zhou, Founder of the Company, was awarded "Zhongguancun High-end Leading Talent"
Image
2011
Image
-Establishment of the Company
-Dr. James Zhou, Founder of the Company, was awarded "Zhongguancun High-end Leading Talent"
-The Company was awarded Anti-tumor Drug Development Engineering Research Center of Guangxi Zhuang Autonomous Region
-The Company obtained from Yale University IP rights and global exclusive license for commercial development of Troxacitabine
Image
2013
Image
-The Company was awarded Anti-tumor Drug Development Engineering Research Center of Guangxi Zhuang Autonomous Region
-The Company obtained from Yale University IP rights and global exclusive license for commercial development of Troxacitabine
-The Company was awarded the National and Local Joint Engineering Research Center for Anti-tumor Drug Development
-The Company obtained from Yale University IP rights for the structure and the exclusive license for commercial development in China of Clevudine's anti-Hepatitis B virus indications
-Dr. James Zhou, founder of the Company, was awarded the Innovation Talents Promotion Program of the Ministry of Science and Technology
-The Company was awarded "Zhongguancun High-tech Enterprise"
-Investment from Guangxi China-Malaysia Park Industrial Platform Investment Co., Ltd.
Image
2015
Image
-The Company was awarded the National and Local Joint Engineering Research Center for Anti-tumor Drug Development
-The Company obtained from Yale University IP rights for the structure and the exclusive license for commercial development in China of Clevudine's anti-Hepatitis B virus indications
-Dr. James Zhou, founder of the Company, was awarded the Innovation Talents Promotion Program of the Ministry of Science and Technology
-The Company was awarded "Zhongguancun High-tech Enterprise"
-Investment from Guangxi China-Malaysia Park Industrial Platform Investment Co., Ltd.
-Troxacitabine, a category 1.1 anticancer drug, was approved by CFDA for phase I-III clinical trials
-Awarded "The Most Promising Innovative Enterprise" of China Venture Capital Forum
Image
2016
Image
-Troxacitabine, a category 1.1 anticancer drug, was approved by CFDA for phase I-III clinical trials
-Awarded "The Most Promising Innovative Enterprise" of China Venture Capital Forum
?The Company was accredited as "National High-tech Enterprise"
?The Company was approved for "Academician Workstation of Guangxi Zhuang Autonomous Region"
?Strategic investment in the Company by Jianfeng Pharmaceutical, a subsidiary of Jianfeng Group (600668.SH)
Image
2017
Image
?The Company was accredited as "National High-tech Enterprise"
?The Company was approved for "Academician Workstation of Guangxi Zhuang Autonomous Region"
?Strategic investment in the Company by Jianfeng Pharmaceutical, a subsidiary of Jianfeng Group (600668.SH)
-68,000 sqm. production base at China-Malaysia Qinzhou Industrial Park in China (Guangxi) Pilot Free Trade Zone was put into operation
-The Company has obtained global exclusive license, IP rights and proprietary technology for the implementation of Siroquine (JP001)
Image
2019
Image
-68,000 sqm. production base at China-Malaysia Qinzhou Industrial Park in China (Guangxi) Pilot Free Trade Zone was put into operation
-The Company has obtained global exclusive license, IP rights and proprietary technology for the implementation of Siroquine (JP001)
-Category 1.1 anti-tumor new drug Troxacitabine commences phase II clinical trial
-Company approved to establish "Workstation of Postdoctoral Scientific Researchers"
Image
2020
Image
-Category 1.1 anti-tumor new drug Troxacitabine commences phase II clinical trial
-Company approved to establish "Workstation of Postdoctoral Scientific Researchers"
-Application for clinical trial for anti-tumor new drug Siroquine has been approved by FDA
-Application for phase III clinical trial for potential breakthrough anti-Hepatitis B drug Clevudine has been approved by CDE
Image
2021
Image
-Application for clinical trial for anti-tumor new drug Siroquine has been approved by FDA
-Application for phase III clinical trial for potential breakthrough anti-Hepatitis B drug Clevudine has been approved by CDE

Drag the mouse to slide

"体育买球网址 "